Guggenheim Downgrades HilleVax (NASDAQ:HLVX) to Neutral

HilleVax (NASDAQ:HLVXGet Free Report) was downgraded by equities researchers at Guggenheim from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday, MarketBeat reports.

Several other research firms have also recently issued reports on HLVX. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of HilleVax in a research report on Friday, May 10th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $5.00 price target (down from $24.00) on shares of HilleVax in a report on Monday. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $9.20.

Check Out Our Latest Analysis on HilleVax

HilleVax Stock Up 3.0 %

Shares of HilleVax stock opened at $1.69 on Monday. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.11. HilleVax has a 52-week low of $1.55 and a 52-week high of $20.22. The company has a market capitalization of $84.03 million, a P/E ratio of -0.51 and a beta of 0.78. The company has a 50 day moving average of $13.28 and a 200 day moving average of $14.68.

HilleVax (NASDAQ:HLVXGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.13). As a group, research analysts forecast that HilleVax will post -3.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Aditya Kohli sold 6,000 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $14.73, for a total value of $88,380.00. Following the completion of the sale, the director now directly owns 764,878 shares of the company’s stock, valued at approximately $11,266,652.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 12,898 shares of company stock valued at $193,766. 71.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On HilleVax

A number of institutional investors have recently modified their holdings of HLVX. Federated Hermes Inc. grew its position in HilleVax by 80.6% during the 3rd quarter. Federated Hermes Inc. now owns 2,113 shares of the company’s stock worth $28,000 after purchasing an additional 943 shares during the last quarter. EntryPoint Capital LLC purchased a new position in shares of HilleVax during the first quarter worth about $80,000. SG Americas Securities LLC acquired a new position in HilleVax in the 4th quarter valued at about $139,000. Tidal Investments LLC purchased a new stake in HilleVax during the 1st quarter valued at approximately $207,000. Finally, abrdn plc acquired a new stake in HilleVax during the 4th quarter worth approximately $433,000. 86.42% of the stock is owned by institutional investors and hedge funds.

HilleVax Company Profile

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

Read More

Analyst Recommendations for HilleVax (NASDAQ:HLVX)

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.